Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

SCH 563705

Catalog No: tcsc0833

Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Specifications

CAS No:
473728-58-4

Formula:
$C_{23}H_{27}N_3O_5$

Pathway:
GPCR/G Protein;Immunology/Inflammation

Target:
CXCR;CXCR

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 30 mg/mL (70.51 mM)

Observed Molecular Weight:
425.48

Product Description

SCH 563705 is a potent and orally available **CXCR2** and **CXCR1** antagonist, with **IC_{50}**s of 1.3 nM, 7.3 nM and **K_i**s of 1 and 3 nM, respectively.

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

IC50 & Target: IC50: 1.3 nM (CXCR2), 7.3 nM (CXCR1)[1], 5.2 nM (Mouse CXCR2)[2]

Ki: 1 nM (CXCR2), 3 nM (CXCR1)[1]

In Vitro: SCH 563705 (Compound 16) is a potent and orally available CXCR2 and CXCR1 antagonist, with IC_{50}s of 1.3 nM, 7.3 nM and K_is of 1 and 3 nM, respectively. SCH 563705 shows potent inhibition against both Gro-a and IL-8 induced human neutrophil migration (chemotaxis IC_{50} = 0.5 nM, against 30 nM of Gro-a; chemotaxis IC_{50} = 37 nM, against 3 nM of IL-8)[1]. SCH 563705 potently inhibits mouse CXCR2 (IC_{50} = 5.2 nM)[2].

In Vivo: SCH 563705 has good oral pharmacokinetic profiles in rats, mice, monkeys and dogs[1]. SCH 563705 (50 mg/kg p.o) reduces blood $Ly6G^+$ $Ly6C^+$ neutrophil frequency and unchanged levels of Ly6GLy6Chi monocytes. SCH563705 (3-30 mg/kg p.o) treatment causes a dosedependent elevation in plasma levels of CXCL1[2].